Study Objective: This study looks at how effective and safe new treatments are for moderate to severe atopic dermatitis (AD), a skin condition causing itchy, inflamed skin.

Study Design: This is a double-blind study, meaning neither the participants nor the researchers know who gets the real treatment or a placebo, which is a harmless pill or treatment used for comparison. Participants will be randomly assigned to different groups to test various treatments, starting with a compound called GHZ339.

• Participants must have had AD for at least one year and be willing to sign a consent form.
• Some medical conditions could exclude participation, like other skin disorders or uncontrolled health issues.
• The study includes multiple visits to the trial center and may involve various tests.

This study is in the Phase II stage, where researchers further evaluate the treatment's safety and how well it works. If you join, you will help scientists learn more about potential new treatments for AD.